Literature DB >> 18767026

Non-peptidic small molecule inhibitors against Bcl-2 for cancer therapy.

Asfar S Azmi1, Ramzi M Mohammad.   

Abstract

A critical regulator of the apoptotic machinery is the Bcl-2 family proteins whose over expression confers a protective effect on malignant cells against death signals of apoptosis. Cancer cells that are resistant to various anti-cancer drugs and treatment regimen are found to over express these Bcl-2 proteins such as Bcl-2, Bcl-X(L), Mcl-1, Bcl-w, and A1/Bfl1. In recent years there has been an exponential growth in the identification as well as synthesis of non-peptidic cell permeable small-molecule inhibitors (SMIs) of protein-protein interaction. The focus of this article is on inhibitors of anti-apoptotic protein Bcl-2. This review summarizes an up to date knowledge of the available SMIs, their mode of action as well as their current status in preclinical as well as clinical development. (c) 2008 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 18767026      PMCID: PMC2577714          DOI: 10.1002/jcp.21567

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  72 in total

1.  Induction of apoptotic program in cell-free extracts: requirement for dATP and cytochrome c.

Authors:  X Liu; C N Kim; J Yang; R Jemmerson; X Wang
Journal:  Cell       Date:  1996-07-12       Impact factor: 41.582

2.  Preclinical studies of a nonpeptidic small-molecule inhibitor of Bcl-2 and Bcl-X(L) [(-)-gossypol] against diffuse large cell lymphoma.

Authors:  Ramzi M Mohammad; Shaomeng Wang; Amro Aboukameel; Ben Chen; Xihan Wu; Jianyong Chen; Ayad Al-Katib
Journal:  Mol Cancer Ther       Date:  2005-01       Impact factor: 6.261

3.  Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death.

Authors:  Z N Oltvai; C L Milliman; S J Korsmeyer
Journal:  Cell       Date:  1993-08-27       Impact factor: 41.582

4.  Gossypol treatment of recurrent adult malignant gliomas.

Authors:  P Bushunow; M M Reidenberg; J Wasenko; J Winfield; B Lorenzo; S Lemke; B Himpler; R Corona; T Coyle
Journal:  J Neurooncol       Date:  1999-05       Impact factor: 4.130

5.  BID: a novel BH3 domain-only death agonist.

Authors:  K Wang; X M Yin; D T Chao; C L Milliman; S J Korsmeyer
Journal:  Genes Dev       Date:  1996-11-15       Impact factor: 11.361

Review 6.  BCL-2 family proteins: regulators of cell death involved in the pathogenesis of cancer and resistance to therapy.

Authors:  J C Reed; T Miyashita; S Takayama; H G Wang; T Sato; S Krajewski; C Aimé-Sempé; S Bodrug; S Kitada; M Hanada
Journal:  J Cell Biochem       Date:  1996-01       Impact factor: 4.429

7.  A preliminary clinical study of gossypol in advanced human cancer.

Authors:  R C Stein; A E Joseph; S A Matlin; D C Cunningham; H T Ford; R C Coombes
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

Review 8.  Bcl-2/Bax: a rheostat that regulates an anti-oxidant pathway and cell death.

Authors:  S J Korsmeyer; J R Shutter; D J Veis; D E Merry; Z N Oltvai
Journal:  Semin Cancer Biol       Date:  1993-12       Impact factor: 15.707

9.  Strand scission in DNA by gossypol and Cu(II): role of Cu(I) and oxygen-free radicals.

Authors:  R Zaidi; S M Hadi
Journal:  J Biochem Toxicol       Date:  1992

10.  Complexes involving gossypol, DNA and Cu(II).

Authors:  R Zaidi; S M Hadi
Journal:  Biochem Int       Date:  1992-12
View more
  47 in total

Review 1.  PAR-4 as a possible new target for pancreatic cancer therapy.

Authors:  Asfar S Azmi; Philip A Philip; Syed F Zafar; Fazlul H Sarkar; Ramzi M Mohammad
Journal:  Expert Opin Ther Targets       Date:  2010-06       Impact factor: 6.902

2.  Vaccinia virus virulence factor N1L is a novel promising target for antiviral therapeutic intervention.

Authors:  Anton V Cheltsov; Mika Aoyagi; Alexander Aleshin; Eric Chi-Wang Yu; Taylor Gilliland; Dayong Zhai; Andrey A Bobkov; John C Reed; Robert C Liddington; Ruben Abagyan
Journal:  J Med Chem       Date:  2010-05-27       Impact factor: 7.446

3.  Bcl-2 phosphorylation confers resistance on chronic lymphocytic leukaemia cells to the BH3 mimetics ABT-737, ABT-263 and ABT-199 by impeding direct binding.

Authors:  Ting Song; Gaobo Chai; Yubo Liu; Xiaoyan Yu; Ziqian Wang; Zhichao Zhang
Journal:  Br J Pharmacol       Date:  2016-01-16       Impact factor: 8.739

4.  Selecting efficacious Bcl-2 family inhibitors for optimal clinical outcome.

Authors:  Irfana Muqbil; Ramzi M Mohammad
Journal:  Ann Transl Med       Date:  2015-11

5.  Measles virus phosphoprotein inhibits apoptosis and enhances clonogenic and migratory properties in HeLa cells.

Authors:  Sankhajit Bhattacharjee; Rishi Kumar Jaiswal; Pramod Kumar Yadava
Journal:  J Biosci       Date:  2019-03       Impact factor: 1.826

6.  The Bcl-2 homology domain 3 mimetic gossypol induces both Beclin 1-dependent and Beclin 1-independent cytoprotective autophagy in cancer cells.

Authors:  Ping Gao; Chantal Bauvy; Sylvie Souquère; Giovanni Tonelli; Lei Liu; Yushan Zhu; Zhenzhen Qiao; Daniela Bakula; Tassula Proikas-Cezanne; Gérard Pierron; Patrice Codogno; Quan Chen; Maryam Mehrpour
Journal:  J Biol Chem       Date:  2010-06-07       Impact factor: 5.157

7.  Effect of miR-451 on the biological behavior of the esophageal carcinoma cell line EC9706.

Authors:  Tao Wang; Wen-Qiao Zang; Min Li; Na Wang; Yu-Ling Zheng; Guo-Qiang Zhao
Journal:  Dig Dis Sci       Date:  2012-10-04       Impact factor: 3.199

Review 8.  Emerging Bcl-2 inhibitors for the treatment of cancer.

Authors:  Asfar S Azmi; Zhiwei Wang; Philip A Philip; Ramzi M Mohammad; Fazlul H Sarkar
Journal:  Expert Opin Emerg Drugs       Date:  2010-09-03       Impact factor: 4.191

Review 9.  Targeting mitochondria in cancer: current concepts and immunotherapy approaches.

Authors:  Sergey Pustylnikov; Francesca Costabile; Silvia Beghi; Andrea Facciabene
Journal:  Transl Res       Date:  2018-07-31       Impact factor: 7.012

Review 10.  Survival signalling and apoptosis resistance in glioblastomas: opportunities for targeted therapeutics.

Authors:  Camilla Krakstad; Martha Chekenya
Journal:  Mol Cancer       Date:  2010-06-01       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.